CVS settles US Justice Department case over opioid prescriptions for $315 million

By Reuters News

By Nate Raymond

Oct 13 (Reuters) - CVS Health CVS.N has agreed to pay $315 million to resolve allegations that the pharmacy chain operator unlawfully filled medically unnecessary prescriptions for addictive opioid painkillers, the US Justice Department said on Tuesday.

The settlement resolves a case that the department announced in 2024 that sought to hold CVS responsible for its role in dispensing massive quantities of dangerous drugs like opioids that were at the heart of a nationwide addiction epidemic.

The lawsuit alleged that since October 2013, CVS illegally filled prescriptions for opioids and other narcotics in violation of the federal Controlled Substances Act and then sought payment from federal healthcare programs like Medicare in violation of the False Claims Act.

As part of the settlement, CVS entered into an agreement with the Drug Enforcement Administration under which it would establish processes to monitor and receive reports of potentially illegal dispensing in its pharmacies and evaluate doctors suspected of illegally prescribing opioids.

"Today's settlement requires CVS to implement additional safeguards to ensure that prescriptions for opioids and other controlled substances are dispensed only when medically appropriate," Assistant US Attorney General Brett Shumate said in a statement.

CVS said in a statement it disagreed with the Justice Department's allegations and was not admitting wrongdoing as part of the settlement.

"Our more than 27,000 CVS pharmacists do their part to help keep America healthy and are highly trained in the safe and appropriate use of all medications," CVS said. "We're pleased to move forward and put this litigation behind us."

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.